Qulipta vs Emgality
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Qulipta | US Emgality | |
|---|---|---|
| Generic name | atogepant | galcanezumab |
| Drug class | CGRP Receptor Antagonist | CGRP Antagonist (Biologic) |
| Treats | Migraine prevention | Migraine prevention, cluster headache |
| Category | Neurology | Neurology |
| Manufacturer | AbbVie | Eli Lilly |
| Year approved | 2021 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $120M | $110M |
| Common side effects | Nausea, Constipation, Fatigue, Decreased appetite | Injection site reactions, Constipation, Itching, Allergic reactions |
Frequently asked questions
Is Qulipta or Emgality better?
Neither is universally "better." Qulipta (atogepant) and Emgality (galcanezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Qulipta and Emgality?
Qulipta is a CGRP Receptor Antagonist made by AbbVie, while Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Qulipta has the larger estimated TV advertising budget of the two.